NCT05932264View on ClinicalTrials.gov

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2025

Conditions
NSCLCNon-small Cell Lung Cancer
Interventions
DRUG

Apatinib + Fluzoparib

Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid

DRUG

Apatinib + Fluzoparib + Adebrelimab

Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w\]

Trial Locations (1)

510060

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT05932264 - Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter